Tilray Brands @tilray·1h
Team USA takes the pitch tonight and @BreckBrew is turning the Beer Garden into match day headquarters!
⚽️ Catch the game on the big screen 🍻 Beer specials all match long 😋 Food specials to keep you fueled 🎯 Make a penalty kick and score a FREE pint
If you're in Colorado, grab your crew, wear your red, white, and blue, and cheer on Team USA with a cold one in hand!
Let’s make some noise! BreckBrew
#TilrayArmy💰🍀 - Today, July 6, 2026, the DEA hearings on cannabis reclassification resumed after the July 4th break. Today was mainly dedicated to presenting the case of the organization Smart Approaches to Marijuana (SAM), one of the main opponents of moving cannabis to Schedule III.
What happened:
England pulled off a miracle winning in Mexico
Until tonight Mexico have only lost 2 games in that stadium in the last 59 years, totaling 89 games. England Red Card and played with 10 men for a large part of the game.
Absolute classic
Big game today!
Don't miss the action at @BrewDog and @tilray @brewpubs
If England or USA reach the final, beers are on us when you wear the winning nation's shirt to our bars (and @tilray @brewpubs).
T&Cs apply. Please enjoy responsibly.
Eyes on $MSOS $TLRY - rescheduling momentum vs state limits. Watch policy vs safety headlines into the open.
Federal momentum toward rescheduling cannabis to Schedule III clashes with state restrictions and fresh health studies. Heading into the July 6 open, investors should weigh policy progress against regulatory and safety headwinds.
Sunday, July 5, 2026 StockAlpha @WolfOfWeedST
The Big Picture
The most impactful development overnight is regulatory, not market action: the DEA told a tribunal it supports moving cannabis from Schedule I to Schedule III. That federal signal could change licensing, research, and banking dynamics if finalized, and it's reshaping how markets and lawmakers think about the industry even while US equities were closed for the long weekend.
At the same time you're seeing diverging state trends and new safety and public perception challenges. Georgia expanded patient access in a way that could dramatically boost the medical market, while North Carolina's Senate voted to restrict hemp THC and kratom products. How will these competing forces affect revenue growth and risk for operators? That's the question investors face heading into Monday's open.
Market Highlights
US stock markets were closed on Sunday. The last trading day was Thursday, July 2, and the next session is Monday, July 6. Here are the top headline facts and figures from the stories affecting the sector.
Key Developments
DEA Hearing: A Potential Shift to Schedule III The DEA's counsel told a federal tribunal that the agency supports moving cannabis to Schedule III. That position could ease research barriers, alter banking and tax treatment, and influence investor sentiment about long-term normalization. If implemented, the change would not instantly solve state-by-state regulatory differences, but it could move the needle on capital formation and credibility for medical claims.
State Divergence: Georgia Expansion Versus North Carolina Restriction
Georgia enacted the Putting Georgia's Patients First Act, which broadens allowed potencies and delivery methods for medical patients, and analysts estimate registered patient counts could triple within a year. That expansion creates a clear, near-term demand opportunity for licensed operators and ancillary businesses in the state.
By contrast, the North Carolina Senate passed a bill to restrict hemp-derived THC and kratom products, effectively banning many products currently on shelves. That action highlights how state-level politics can blunt national progress and create patchwork markets. For companies operating across states, compliance complexity and inventory risk will remain central issues.
Safety, Research, and Public Perception Questions
A large longitudinal study found that teens who used cannabis had significantly higher risks of later developing psychotic disorders, bipolar disorder, depression, and anxiety. The reported doubling of risk for psychotic and bipolar disorders will likely feed calls for tighter youth access controls and targeted public health campaigns. You're likely to hear this study cited in legislative debates and compliance discussions.
Meanwhile, transportation and safety groups are urging federal authorities to clarify rules on drug testing after rescheduling. Their letter stresses concerns for truck drivers, pilots, and transit workers, which could slow implementation of any federal change or lead to worker-specific carve outs. How regulators balance workplace safety and criminal policy reform is now a live question for investors and operators alike.
What to Watch
You'll want to monitor the DEA tribunal and any formal rulemaking timelines closely. Will the agency publish a proposed rule and a comment period, or will Congress try to legislate change? Regulatory process timelines will determine how quickly the market can price in meaningful structural benefits.
State-level moves matter as much as federal ones. Watch for implementation guidance from Georgia regulators as new patient registration ramps up. Also track North Carolina's next steps and any legal challenges from businesses affected by the restrictions. Which states move to expand access next, and which will tighten rules?
Keep an eye on public perception and safety-driven policy responses. Expect advocacy from transportation groups and health organizations that could shape workplace testing rules and marketing limitations. You should also watch the investor reaction in the ETFs and names that follow the sector, including $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY, when markets reopen on July 6.
Bottom Line
We’re celebrating with fresh beers flown in from the USA and an All-American tasting flight. 🍻
BrewDog Treats members can also claim one FREE standard serve of any participating Fresh From The USA Tilray guest beer between 3–5 July when you scan your Treats wallet✨
📍 BrewDog Canary Wharf 📅 Saturday 4 July 2026
One redemption per member. Participating draught beers only. T&Cs apply.
Canada won't be replaced as the main German Cannabis supplier so quickly—rescheduling or not.
The USA plans to downgrade cannabis from the highest risk level to Schedule III.
For German patients, nothing changes in the short term.
The path from a US decision to an open export market to Europe is a long one.
For American patients, however, it would be real progress. Schedule III means: Cannabis is officially recognized as medicine, research becomes easier, and insurance companies could reimburse treatments for the first time.
MedCanOneStop
Starting July 1, 2026, nationwide: Pharmacies will be permitted to actively support patients during medical video consultations.
The so-called assisted telemedicine (aTM) will thus officially become part of the framework agreement under § 129 SGB V.
For the provision of medical cannabis, this represents a significant shift: Pharmacies and telemedicine are structurally moving closer together.
We are addressing this in exchange with our partner pharmacies to create meaningful additions for treatment with medical cannabis from it.
MedCanOneStop
Pillar 2 Recreational Cannabis Coming Soon to Germany?
Streeck, serves in the Federal Ministry of Health as the Federal Government Commissioner for Drug and Addiction Policy and is a member of the Bundestag. Streeck is the Federal Government Commissioner for Drug and Addiction Policy
July 3, 2026 MedCanOneStop
On June 5, 2026, Federal Drug Commissioner Hendrik Streeck (CDU) spoke out for the first time to the Redaktionsnetzwerk Deutschland in favor of cannabis model projects, including the option of using specialty shops as distribution points. An unusual step for a CDU politician, whose party has officially labeled partial legalization a mistake.
Just under four weeks later, on July 2, 2026, Streeck followed up with the Rheinische Post: Pharmacies as sales outlets within the framework of pilot projects, explicitly as his personal opinion. The direction remains the same, but the framework becomes more concrete.
Streeck himself put it this way in June: “If cultivation associations are regulated in such a complicated way that they can hardly function, no control is created, but rather evasion behavior. Then one must honestly talk about simplifications.”
🇨🇦 Canada vs. Morocco 🇲🇦 🇵🇾 Paraguay vs. France 🇫🇷 🇧🇷 Brazil vs. Norway 🇳🇴 🇲🇽 Mexico vs. England 🏴 🇵🇹 Portugal vs. Spain 🇪🇸 🇺🇸 USA vs. Belgium 🇧🇪 🇦🇷 Argentina vs. Egypt 🇪🇬 🇨🇴 Colombia vs. Switzerland 🇨🇭
Published on July 3, 2026 By MarijuanaMoment
“There was no discussion of the lasting harms of marijuana criminalization itself—the arrests, convictions, incarceration and collateral consequences that continue to affect individuals, families and communities.”
By Cat Packer, Drug Policy Alliance
At 7:15 Monday morning, I was standing outside the Drug Enforcement Administration (DEA)’s headquarters in Arlington, Virginia, waiting to attend one of the most consequential federal marijuana proceedings in decades: the DEA’s hearing on whether marijuana should be moved from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Although the Drug Policy Alliance, where I work, sought permission to participate as an interested party, DEA denied our request, along with those submitted by organizations including NORML, Marijuana Policy Project, Cannabis Regulators of Color Coalition, Latino Cannabis Alliance, Law Enforcement Action Partnership, Doctors for Drug Policy Reform, the Parabola Center for Law & Policy, Supernova Women and Students for Sensible Drug Policy.
Many of these organizations have spent decades at the forefront of marijuana reform that addresses the harms of criminalization, prioritizes health, and delivers legalization that puts communities first–but were notably excluded from participation in the hearing.
Instead, the DEA designated just seven parties to participate—and every one of them opposes rescheduling.
The hearing wasn’t scheduled to begin until 9:00 a.m.—but members of the public were admitted on a first-come, first-served basis, and only a handful at a time. There was no livestream. No video broadcast. No public audio feed. If you wanted to know what was happening inside the hearing room, you had to be there.
For the first two days, I was.
On the third day, I was denied entry after being told the administrative law judge had barred public attendees after 8:50 a.m.—a restriction that had not been publicly disclosed.
Most people simply don’t have the time, flexibility or financial resources to attend a hearing like this in person. I recognize that I am fortunate to have a job that gave me the opportunity to do so. I believed it was important to attend—not only to better understand the proceeding firsthand, but also to help explain to the public what this hearing is and what it means.
From the outset, DEA framed the proceedings as advancing “regulation, not legalization.” But regulation and legalization are not competing goals—they are complementary responsibilities. By refusing to acknowledge that most Americans have embraced marijuana legalization and by excluding many of the voices that helped make those reforms possible, the hearing failed to address the central questions Americans have about the future of marijuana policy.
After spending two days inside the hearing room—and being denied access on the third—three observations stood out.
My first observation was: This conversation is being shaped by a narrow set of voices—those of DEA and of opponents of marijuana reform.
On one side of the room sat the federal government, represented by DEA and its legal counsel, defending its proposal to move marijuana to Schedule III. On the other side, sat the legal counsel of the seven designated participants selected by DEA—every one of whom opposes rescheduling.
That matters because beyond DEA, these parties are the only ones permitted to present witnesses, introduce evidence and cross-examine the government’s experts. Their testimony—and the testimony they challenge—will help shape the administrative record the administrative law judge will review before making a recommendation to DEA.
When many of the stakeholders most directly affected by federal marijuana policy are excluded from participating, the record inevitably reflects a narrower range of perspectives.
That became especially clear as the testimony unfolded.
Dr. Dominic Chiapperino, Director of the Controlled Substances Section at the Food and Drug Administration (FDA), shared testimony that was generally limited to FDA’s scientific and medical review—the process used to determine marijuana’s currently accepted medical use, abuse potential and the methodology supporting the recommendation to reschedule marijuana.
The government’s second witness, Dr. Corey Burchman, shifted the discussion from scientific analysis to clinical practice. Drawing on his experience treating patients, he described helping many patients transition from opioids to cannabis and discussed the relative risks of opioid use and marijuana.
These issues are important and deserve thoughtful consideration. But so do the perspectives that weren’t represented.
There was no discussion of the lasting harms of marijuana criminalization itself—the arrests, convictions, incarceration and collateral consequences that continue to affect individuals, families and communities. There was no discussion of the racial disparities that have characterized marijuana enforcement for decades, the Nixon-era Shafer Commission’s recommendation against criminalizing personal marijuana possession or the lessons learned from the dozens of states that have legalized and regulated marijuana.
If we are evaluating marijuana’s place under federal law, we should also evaluate these issues and the consequences of the federal policies that have governed it for more than half a century. Questions around marijuana criminalization and the social and financial cost of enforcement are central to evaluating whether the current system serves the public interest.
My second observation was: This hearing is about marijuana. Not medical vs. adult use.
Much of the recent public discussion surrounding these proceedings has focused on what rescheduling might mean for adult-use cannabis. But from the outset, government counsel made clear that, in DEA’s view, “this is not about recreational cannabis. This is about regulation, not legalization.”
But what’s important about an acknowledgement that this isn’t about ‘recreational,’ in part, is the reality that the CSA does not distinguish between “medical marijuana” and “recreational marijuana.” It regulates “marihuana” as a single defined substance, and this hearing is considering whether that substance—as defined in the CSA—should move from Schedule I to Schedule III.
There is one important exception. Earlier this year, DEA finalized a separate rule moving FDA-approved marijuana medications and marijuana produced by qualifying state-licensed medical marijuana operators into Schedule III. Those decisions are already final and are not being reconsidered here. Everything else that falls within the federal definition of marijuana remains in Schedule I and criminalized under federal law.
My third observation was: This hearing matters—but it fails to consider or address the biggest questions facing marijuana reform.
This hearing is only one step in the administrative process.
Every question asked and every answer given becomes part of the official record. Once the hearing concludes, the administrative law judge will compile that record and issue a recommended decision to DEA. The agency will then determine whether to issue a final rule, and whatever decision it reaches will almost certainly face judicial review.
In other words, this hearing matters—but it is not the final word.
That brings me back to the government’s opening statement: that this proceeding is “about regulation, not legalization.”
The American people have repeatedly made clear that they are ready to move beyond marijuana criminalization. They also expect thoughtful regulation that protects public health, supports scientific research, creates clear rules for legitimate businesses, draws on the lessons learned by states and begins repairing the harms created by decades of prohibition.
Legalization and regulation are not mutually exclusive. Nor do they have to be competing goals. They should be complementary responsibilities.
Rescheduling may change marijuana’s status under federal law, but it will not end federal criminalization, resolve the conflict between federal and state law or create the comprehensive regulatory framework the country increasingly needs and expects. Those are questions that only Congress can answer.
That is why, regardless of how DEA ultimately rules, Congress should advance comprehensive marijuana reform through legislation such as the Marijuana Opportunity Reinvestment and Expungement (MORE) Act and the Cannabis Administration and Opportunity Act (CAOA). Ending federal marijuana criminalization, supporting state-regulated systems, restoring rights, releasing those still incarcerated for marijuana offenses and beginning to repair the harms of prohibition are not separate from the conversation about regulation—they are essential to it.
I won’t be able to attend the remainder of the hearing in person. Like most members of the public—and like the many organizations and experts denied the opportunity to participate as designated parties—I will be waiting to see what ultimately comes from a process that has been both exclusionary and lacking in transparency.
What I already know, however, is this: if we want a marijuana policy that protects public health, advances evidence-based regulation, addresses the harms of prohibition, and reflects the will of the American people, we need both legalization and regulation.
Cat Packer is the director of drug markets & legal regulation at the Drug Policy Alliance and a distinguished cannabis policy practitioner in residence at The Ohio State University Moritz College of Law Drug Enforcement and Policy Center. From 2017 through 2022, Packer served as the first executive director of the City of Los Angeles Department of Cannabis Regulation.
By Ben Stevens July 3, 2026
France’s incoming generalised medical cannabis framework has edged tantalisingly close to clearing its last remaining hurdle, as the outstanding decree governing the reimbursement of cannabis medicines has been submitted to France’s highest administrative court.
Two weeks ago, Business of Cannabis reported that France’s health minister had confirmed that these delayed regulatory texts needed to push through medical cannabis generalisation would be published in July.
According to Newsweed, the Minister Delegate for Relations with Parliament confirmed this week that the text had received approval from the Ministry of Economy, Finance and Industrial and Digital Sovereignty, and the decree was submitted to the Conseil d’État on 2 July.
Now, the Conseil d’État must complete its legal review, the final step before it is published in the Journal Officiel, and becomes law.
The review is expected to complete over the summer recess, with the government targeting publication at the opening of the autumn parliamentary session on 1 October.
Why is the decree so important?
Without this decree, France’s entire reimbursement process cannot move forward. The Haute Autorité de Santé’s (HAS) Transparency Commission, the body that formally decides which medicines qualify for national health coverage, is legally unable to open evaluation sessions until the procedural framework established by this decree has been published.
HAS was tasked with evaluating cannabis medicines by the health minister in March 2025, and published its methodology in July 2025. By the first quarter of this year it had received manufacturer dossiers and completed preparatory analysis. The committee was ready, but the evaluations were not because the decree was not there.
The text defines how the Transparency Commission conducts its assessment, including how manufacturers submit dossiers, what evidence is considered, how the commission deliberates, and on what timeline. Critically, it does not itself set reimbursement rates, those follow from the HAS opinion, which in turn triggers price negotiations with the state. As such, this decree is more the starting gun than the finish line.
The indications in covered remain the same five which were established in the pilot trial in 2021, namely refractory neuropathic pain, refractory epilepsy in adults and children, painful spasticity from multiple sclerosis or other central nervous system conditions, oncology-related refractory symptoms, and advanced palliative care.
All are last-resort, meaning patients must have exhausted available alternatives before cannabis medicines can be considered.
What the decree is likely to contain
While the final text will not be available to the public until it is published, in February Business of Cannabis detailed the draft framework presented to industry stakeholders at Cannabis Europa Paris, the first concrete view of the government’s proposed economic model.
At that stage, the draft proposed a tiered reimbursement structure tied directly to HAS’s assessment of each product’s therapeutic benefit, with coverage rates set at 65%, 30%, 10%, or 0%, corresponding to major, moderate, minor, or insufficient benefit respectively.
Since the majority of eligible patients suffer from long-term conditions that qualify for ALD (affection de longue durée) status under the French system, most could access cannabis medicines at 100% coverage regardless of their base reimbursement tier, though that question was still being finalised at the time.
Pricing under the draft model would be structured by homogeneous product categories, grouping medicines by pharmaceutical form, composition, and clinical characteristics, with a single price applied across each category, fixed for three years and revisable if new clinical evidence emerges.
Whether the final text reflects those proposals precisely is unknown. The draft went through a stakeholder consultation period of three to four weeks following the February meeting, and the government will have incorporated feedback before submitting the final text.
The Conseil d’État may also request modifications during its own review. The published decree, when it arrives, may differ in detail, but the economic architecture described in February has not been publicly contradicted.
If the review completes over the summer and the decree is published at the parliamentary opening on 1 October, HAS could deliver its reimbursement opinion before the year is out, with price negotiations to follow and first prescriptions under a permanent framework possible in 2027. The roughly 700 patients still enrolled in the pilot are covered until 31 December 2026, a deadline that now looks, for the first time in five years, like it might not need to be extended again.
Brewbound
⚽🍺 England and Atlanta are among the big beer winners from the World Cup, with Insider’s Week in Beer breaking down the tournament’s impact and other industry storylines.
While U.K. football fans may have been cheering loudly at the amazing Harry Kane 2-goal performance in the ENGLAND vs. DR CONGO match this week, chances are U.K. pub owners were cheering louder...
NOTE: Tilray is all over both those areas
https://newsletter.bevnet.com/login/2/bad6b506239d4c3b9798aa90e79b4d75
July 3, 2026 Reuters
Summary
Hot summer weather usually provides a boost for alcohol sales Extreme heat can reverse the trend, companies and analysts say Carlsberg offers more low- and no-alcohol drinks, soft drinks Heat can also hurt economies and agriculture, denting spending LONDON, July 3 (Reuters) - Extreme heat in Europe is testing the assumption that hot summers mean a boost in sales of alcohol, with studies showing drinkers less inclined to reach for a chilled beer or Aperol Spritz when it gets too hot. Alcohol sales on average rise with temperature up to just over 32 degrees Celsius, after which the positive effect becomes smaller, researchers from the University of California, ETH Zurich and North Carolina State University found.
The effect varied by geography and was less pronounced in already warm regions, said the March research paper, which was based on U.S. retail sales data between 2006 and 2023. "Generally warm weather is good for consumption. But there is also an upper limit ... beyond which it's just uncomfortably hot," said Marten Lodewijks, president of drinks market research firm IWSR, adding this reverses the trend for some drinkers.
Europe's summer heatwave, which began on June 20, was the most intense recorded on the continent, causing thousands of excess deaths and overwhelming healthcare systems, disrupting power generation and damaging infrastructure.
European health authorities said people should avoid alcohol, which increases dehydration and body heat. Its consumption and sales in stores were briefly banned in Paris.
"There is an important difference between warm weather and extreme heat," said Carlsberg's (CARLb.CO), opens new tab global director of public affairs Kristian Henningsen, adding that extreme heat can push people to stay inside rather than go out for a drink.
The Danish brewer is focused on offering drinkers more choices, such as low- and no-alcohol beers or soft drinks, partly to adapt to such changes, Henningsen told Reuters.
Other major beer and spirits makers either declined to comment or did not respond to requests for comment on the likely effects of more extreme weather on their business.
Top brewers such as Anheuser-Busch InBev (ABI.BR), opens new tab have previously blamed unseasonably cold or wet weather for disappointing earnings during the summer, when drinkers have normally turned to chilled, lighter drinks such as beer. 161.2 per dollar is where the yen recovered to on Friday, having bounced from a 40-year low on Tuesday.
Another major beer maker told Reuters that weather is one of the main metrics it considers when forecasting beer sales. David Lambert, a 59-year-old parish priest in London, said he was less inclined to reach for an alcoholic drink during Britain's recent extreme weather when temperatures hit a record-breaking 37.7 degrees Celsius in Norfolk, eastern England.
"I certainly didn't drink as much alcohol last week. You can't... It just makes you docile, tired, not with it," Lambert told Reuters at London's The Sun Wharf.
Bar staff at the JD Wetherspoon (JDW.L), opens new tab pub were busier than usual during the heatwave, shift leader Yash Hitesh Hansora told Reuters, with drinkers who initially sought outdoor space, which The Sun Wharf does not offer, soon asking for air-con and ice.
Spiros Malandrakis, global insights manager for alcoholic drinks at Euromonitor International, said more extreme heat could have mixed effects for those in the drinks trade.
As well as pushing some to drink less, heatwaves can hurt economies and spending power and hit agriculture, increasing alcohol production costs, he said.
Malandrakis also predicted some people will drink more in a world that "feels like it's literally on fire".
The EU's Copernicus Climate Change Service said heatwaves will become more frequent and intense, while scientists said Europe's heatwave would have been virtually impossible without human-caused climate change, which is warming it at a faster rate than any other continent.
For some, the heat is still the perfect excuse for a drink.
"There's just something about the sunshine that makes you want to pour a glass of wine," said Teresa Angell, a 57-year-old working in billing support in London.
Tomorrow's the Fourth of July! 🎆
Make sure to stock up and sweeten the celebration with Blue Point Brewing's Blueberry Ale.
Set off some fireworks with a can in hand.
Tilray Brands
The DOJ publicly criticized vested interests opposing cannabis rescheduling, a development that strengthens federal policy momentum. Analysts and investors will be watching regulatory signals and product research as markets are closed for the holiday.
Friday, July 3, 2026 StockAlpha @WolfOfWeedST
The Big Picture
The Department of Justice publicly criticized what it called "pocketbook interests" that are opposing federal cannabis rescheduling, a development that adds momentum to long-running policy discussions. That statement, reported by Marijuana Moment on Jul 3, comes alongside state-level reform talk and consumer polling that suggest public and political support is aligning in favor of eased restrictions.
For you as an investor, policy shifts matter because they influence access, banking, research, and tax treatment across the industry. With U.S. markets closed for Independence Day observance, the news is arriving while traders are offline, so there may be heightened attention when markets reopen on Monday, Jul 6.
Market Highlights
U.S. equity markets are closed today for the Independence Day holiday, last trading activity was on Thursday, Jul 2, and markets reopen on Monday, Jul 6. That means near-term price moves in the Cannabis sector will be driven by headlines and weekend developments.
Policy spotlight: DOJ rebuked opponents to rescheduling, framing some resistance as driven by narrow financial interests, according to Marijuana Moment on Jul 3.
State-level reform: Illinois' governor highlighted new marijuana reforms in the same newsletter, keeping state policy on the radar.
Public sentiment: A poll cited by Marijuana Moment indicated Americans broadly back the Supreme Court's rulings tying into cannabis issues, a sign of shifting public opinion.
Scientific angle: The newsletter flagged a study on terpenes and the entourage effect, a development that could affect product differentiation and consumer demand.
Stocks to watch heading into the long weekend include sector ETFs and major operators such as $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY, with final session prices as of Thursday, Jul 2.
Key Developments
DOJ Public Statement Strengthens Rescheduling Debate The Department of Justice publicly criticized what it called 'pocketbook interests' that oppose rescheduling cannabis, a strong signal that federal law enforcement and parts of the executive branch are open to reexamining classification. That kind of language can influence administrative processes and the framing of subsequent agency actions, and it may increase the probability of regulatory movement in the months ahead.
What does this mean for the market?
Greater clarity on rescheduling would ease some compliance and banking frictions and potentially broaden institutional participation over time. You should expect policy headlines to be a key volatility driver when markets reopen.
State Reforms and Public Opinion Keep Pressure on Federal Policy Illinois' governor touting new reforms and a poll showing public support for related Supreme Court rulings suggest political cover for federal action. Those developments often act in tandem, because governors and public opinion shape congressional priorities and administrative discretion.
For investors, coordinated momentum across state and federal levels increases the chance that incremental reforms will follow, including more permissive banking guidance or research access. How fast those changes arrive is an open question, but the tide may be turning in favor of decriminalization and regulatory normalization.
What to Watch
With markets closed today, you'll want to track policy and research developments over the holiday and be ready for market reaction when trading resumes on Monday, Jul 6. Here are the immediate catalysts and risks to monitor.
Regulatory calendar: Watch for follow-up statements from the DOJ, DEA, and HHS, along with any formal petitions or administrative timelines that could indicate a rescheduling process.
Legislative signals: Check for congressional hearings or new bills that reference rescheduling, federal banking access, or tax code changes for cannabis businesses.
State moves: Keep an eye on Illinois implementation details and other state-level reforms that could set precedents for broader policy shifts.
Scientific and product news: Further research on terpenes and the entourage effect could influence product development, branding, and margins for producers, especially those focused on differentiated extracts.
Sector liquidity and ETF flows: Monitor trading and fund flows in $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY when markets reopen, since policy headlines often drive short-term reallocation.
Risk factors: Opposition from well-funded industry groups, legal challenges, or slow administrative timelines could delay progress. How will you balance policy optimism against execution risk?
Bottom Line
DOJ's public critique of opponents to rescheduling is a notable policy signal and could accelerate administrative moves, analysts note.
State reforms and polling data add political momentum, but timing for concrete federal change remains uncertain heading into next week.
Product-level research, like the terpene study, could create differentiation and affect margins for producers and branded product players.
Keep an eye on $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY when markets reopen, as policy headlines often drive near-term volatility.
This briefing is informational. Data suggests shifting momentum, but caution is warranted until regulatory actions are formalized.
FAQ Section
Q: What does DOJ criticism of opponents to rescheduling mean for federal policy?
A: The DOJ statement increases political and administrative pressure on agencies to reassess rescheduling, but formal changes require agency action and can take months.
Q: Will state reforms speed up federal change?
A: State reforms create practical precedents and political momentum that can influence federal timelines, but they do not automatically change federal scheduling or tax rules.
Q: How should I track market impact over the holiday?
A: Markets are closed today, so monitor policy releases, weekend headlines, and ETF flows for $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY ahead of reopening on Monday, Jul 6.
Investment disclaimer: This article presents analysis and reported facts for informational purposes only. It does not recommend buying, selling, or holding any security, and it is not personalized investment advice.
Gather the crew and raise a pint at BrewDog's in Ohio and Las Vegas.
We've got everything you need to celebrate: a special holiday food menu, plenty of cold craft beer, a live DJ bringing the vibes, and Kona Ice truck for the whole family to enjoy. 🎆🎶
Tilray Brands
This Fourth of July, bring back your favorite summer memories. ☀️🍧
From classic nostalgic flavors to backyard BBQs and fireworks, Popsicle Hard is the perfect way to celebrate.
Stock up now and make every sip taste like summer.
Tilray Brands